Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...
The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...
A new anti-HER2 IgE antibody potentially offers new therapy options for treatment-resistant breast and ovarian cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback